[Therapy of porphyrias].
D000208:Acute Disease; D000227:Adenine Nucleotides / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D001639:Bicarbonates / Q000627:therapeutic use*; D001815:Bloodletting; D003676:Deferoxamine / Q000627:therapeutic use; D004035:Diet Therapy; D004492:Edetic Acid / Q000627:therapeutic use; D006801:Humans; D010743:Phospholipids / Q000627:therapeutic use; D011164:Porphyrias / Q000628:therapy*; D011732:Pyridoxal Phosphate / Q000627:therapeutic use*; D011837:Radiation-Protective Agents; D006435:Renal Dialysis
D000227:Adenine Nucleotides; D000962:Antimalarials; D001639:Bicarbonates; D010743:Phospholipids; D011837:Radiation-Protective Agents; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; D003676:Deferoxamine
Die Therapie der Porphyrien.